Santhera Proposes Changes to its Board of Directors

Santhera's Board proposes its Shareholders to appoint Jürg Ambühl as new member of the Company's Board for a term of two years until the ordinary Shareholders Meeting in 2011. Mr. Ambühl is a Swiss citizen and born in 1949. He is a seasoned marketing specialist with a long track record in the pharmaceutical industry globally. Mr. Ambühl holds a PhD in chemistry from the Swiss Federal Institute of Technology, Zurich (ETH), Switzerland and an MBA from the INSEAD, Fontainebleau, France. He started his professional career at Eli Lilly's subsidiary in Germany, where, from 1978 to 1982, he held several management positions in sales and marketing.

From 1982 to 1987, Mr. Ambühl worked for McKinsey. From 1987 to 1989, he held several senior management positions within MSD Sharp & Dohme in Germany, lately as general manager with business responsibility for the German market. From 2000 to 2001, Mr. Ambühl served as president regional business Europe/international at Knoll/BASF Pharmaceuticals. From 2001 to 2003, he served as chief executive officer of Metagen Pharmaceuticals, a Berlin-based oncology spin-off of Schering. From 2003 to 2007, he worked in several senior management positions for the Serono group, lastly as senior executive vice president global marketing. In this capacity, he was responsible for worldwide marketing strategies for all of Serono's products. Currently, Mr. Ambühl is partner of Ares Life Sciences.

In addition, the Board proposes to re-elect Michael Lytton and Hans Peter Hasler for a term of one year each (until the Annual Shareholders' Meeting in 2010) and Timothy Rink for a term of three years (until the Annual Shareholders' Meeting in 2012). Rudolf Gygax, member of the Board since 2004 and serving also in the Board's Audit Committee and Nomination & Compensation Committees, has decided not to stand for re-election for personal reasons.

"We are very pleased to nominate such a prominent marketing specialist as Jürg to our Board of Directors. His international know-how in Marketing & Sales will add significantly to the Board's expertise in this key area, as Santhera prepares its first commercial launch in the US market. I am confident that Jürg will provide important and valuable advice and I look forward to working with him", said Michael Lytton, Chairman of the Board of Santhera. "We express our sincerest thanks to Ruedi for his highly valued contributions during many years. As representative of the Novartis Venture Fund, he was a Board member of MyoContract, one of our two predecessor companies, and in this function, fundamentally involved in the founding and development of Santhera."

2008 Annual Report The interactive version of Santhera's 2008 Annual Report is available on the Company's Web site www.santhera.com/2008interactive. The report can also be downloaded as pdf-file from www.santhera.com/reports.

Editor's note: Image rights belong to the respective publisher.